Physician profile
Peter J Krall
NPI 1780818005
$6,661.53
in general payments reported to CMS, 2019-2025
29 companies · $742 in 2025
The $742 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,139 · 2020: $996 · 2021: $682 · 2022: $660 · 2023: $1,216 · 2024: $1,227 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,171 · Entertainment: $13.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,171.19 |
| Entertainment | $13.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,430.57 | 2019-2025 | Argos, Hydrus Microstent, Clareon |
| Bausch & Lomb Americas INC. | $820.03 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $456.90 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $423.34 | 2020-2024 | Acthar |
| Abbvie INC. | $414.67 | 2022-2025 | |
| Allergan, INC. | $261.16 | 2019-2022 | |
| Oyster Point Pharma, INC. | $257.63 | 2022-2025 | Tyrvaya, Ryzumvi |
| New World Medical,INC. | $250.20 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $249.97 | 2019-2021 | |
| Biotissue Holdings INC. | $214.08 | 2025 | |
| Kala Pharmaceuticals, INC. | $212.72 | 2019-2020 | |
| Glaukos Corporation | $200.07 | 2022-2025 | Idosetr |
| Sight Sciences, INC. | $198.18 | 2022-2025 | Omni Surgical System |
| Ivantis, INC | $190.63 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $156.85 | 2024 | Veracity Surgical |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $143.90 | 2019-2020 | |
| Harrow Eye, LLC | $139.08 | 2023-2025 | Vevye, Iheezo |
| Shire North American Group INC | $126.22 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $110.89 | 2019-2021 | |
| Thea Pharma INC. | $105.89 | 2023-2025 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $58.45 | 2020 | |
| Dompe US, INC. | $57.36 | 2024-2025 | Oxervate |
| Genentech USA, INC. | $52.18 | 2024-2025 | Vabysmo |
| Amgen INC. | $32.80 | 2024 | Tepezza |
| Alcon Research LLC | $25.87 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $22.09 | 2025 | Xdemvy |
| Horizon Therapeutics Plc | $18.64 | 2022 | |
| Glaxosmithkline, LLC. | $17.18 | 2025 | Blenrep |
| Optos, INC. | $13.98 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Krall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.